EligibleTrials

Vitamin D for Prostate Endocrine Therapy

Recruiting · NCT05838716 · Interventional (participants receive a specific treatment) · Lead sponsor: University of Rochester

View the official record on ClinicalTrials.gov →
Prostate cancer

Interventions studied

Biospecimen CollectionD VitaminDual X-ray AbsorptiometryPlacebo AdministrationQuality-of-Life AssessmentQuestionnaire Administration

What this trial is about

This phase III trial tests whether high-dose vitamin D works in treating androgen-deprivation therapy (ADT)-induced bone loss in patients with prostate cancer who are undergoing androgen-deprivation therapy. Vitamins are substances that the body needs to grow and develop normally. Vitamin D helps the body absorb calcium. Calcium is one of the main building blocks of bone. A lack of vitamin D can lead to bone diseases such as osteoporosis or rickets. This trial may help researchers determine if high-dose vitamin D helps keep bones strong, lowers number of falls, and lessens fatigue in men getting androgen-deprivation therapy.

Who can take part

Age range
50 Years and older
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

51 locations listed across 14 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.